Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Mar;41(3):709–711. doi: 10.1128/aac.41.3.709

Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.

K E Aldridge 1, D S Ashcraft 1
PMCID: PMC163778  PMID: 9056020

Abstract

Bay 12-8039, a new 8-methoxy quinolone, was compared with other agents for activity against clinically relevant anaerobes. Bay 12-8039 inhibited 91 and 96% of the 410 test isolates at 2 and 4 micrograms/ml, respectively. Bay 12-8039 had activity comparable to that metronidazole and overall was at least 16-fold more active than ciprofloxacin, ofloxacin, and cefoxitin, 32-fold more active than cefotetan, and at least 128-fold more active than penicillin G.

Full Text

The Full Text of this article is available as a PDF (57.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldridge K. E., Gelfand M., Reller L. B., Ayers L. W., Pierson C. L., Schoenknecht F., Tilton R. C., Wilkins J., Henderberg A., Schiro D. D. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States. Diagn Microbiol Infect Dis. 1994 Apr;18(4):235–241. doi: 10.1016/0732-8893(94)90026-4. [DOI] [PubMed] [Google Scholar]
  2. Aldridge K. E., Sanders C. V., Lewis A. C., Marier R. L. Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production. J Med Microbiol. 1983 Feb;16(1):75–82. doi: 10.1099/00222615-16-1-75. [DOI] [PubMed] [Google Scholar]
  3. Eley A., Greenwood D. Beta-lactamases of type culture strains of the Bacteroides fragilis group and of strains that hydrolyse cefoxitin, latamoxef and imipenem. J Med Microbiol. 1986 Feb;21(1):49–57. doi: 10.1099/00222615-21-1-49. [DOI] [PubMed] [Google Scholar]
  4. Goldstein E. J. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States. Clin Infect Dis. 1993 Jun;16 (Suppl 4):S377–S381. doi: 10.1093/clinids/16.supplement_4.s377. [DOI] [PubMed] [Google Scholar]
  5. Huth R. G., Acebo R., Matthew E. B. Osteitis cystica tuberculosa multiplex in a patient infected with human immunodeficiency virus. Clin Infect Dis. 1994 Feb;18(2):260–261. doi: 10.1093/clinids/18.2.260. [DOI] [PubMed] [Google Scholar]
  6. Nord C. E., Lindqvist L., Olsson-Liljequist B., Tunér K. Beta-lactamases in anaerobic bacteria. Scand J Infect Dis Suppl. 1985;46:57–63. [PubMed] [Google Scholar]
  7. Sato K., Matsuura Y., Inoue M., Mitsuhashi S. Properties of a new penicillinase type produced by Bacteroides fragilis. Antimicrob Agents Chemother. 1982 Oct;22(4):579–584. doi: 10.1128/aac.22.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Wexler H. M., Molitoris E., Reeves D., Finegold S. M. In vitro activity of DU-6859a against anaerobic bacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2504–2509. doi: 10.1128/aac.38.10.2504. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES